Ying Xie

Dr. Ying Xie

Department of Gastroenterology, Shengjing Hospital of China Medical University
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Gut and Liver
Verified
Journal Article
Open access
PDF file
LZLinyan Zhou
Linyan Zhou
DLDongyan Liu
Dongyan Liu
YXYing Xie
Ying Xie
XYXinjie Yao
Xinjie Yao
YLYan Li
Yan Li
Linyan Zhou, Dongyan Liu, Ying Xie, Xinjie Yao, and Yan Li. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18316

1 August 2020 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
YXYing Xie
Ying Xie
LZLinyan Zhou
Linyan Zhou
XYXinjie Yao
Xinjie Yao
YLYan Li
Yan Li

12 February 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
MLManning Li
Manning Li
YXYing Xie
Ying Xie
Background: Helicobacter pylori (H. pylori) is highly prevalent worldwide and is closely associated with many gastric conditions. Current methods for eradicating H. pylori include triple or quadruple therapy, including antibiotics, proton pump inhibitors, and bismuth agents; however, with antibiotic abuse and increased drug resistance rates, the effectiveness of traditional methods is gradually decreasing, with many adverse effects such as abdominal pain, diarrhea, and intolerance. In recent years, there has been controversy regarding whether adding Saccharomyces boulardii (S. boulardii) to traditional therapies is beneficial for eradicating H. pylori.Aim: To evaluate the efficacy and safety of S. boulardii as an adjuvant therapy for the eradication of H. pylori.Methods: We systematically searched the PubMed and Web of Science databases from January 2002 to January 2023. The primary outcome was the H. pylori eradication rate. The secondary outcomes included total adverse effects, abdominal pain, diarrhea, bloating, constipation, nausea, vomiting, taste disorders, and other adverse reactions. We evaluated the included studies for publication bias and heterogeneity. Fixed- and random-effects models were used for studies without and with heterogeneity, respectively, to calculate the risk ratios (RRs) and conduct sensitivity and subgroup analyses.Results: Nineteen studies comprising 5,036 cases of H. pylori infection were included in this meta-analysis. The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08–1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37–0.66), diarrhea (RR=0.36, 95% CI: 0.26–0.48), abdominal distension (RR=0.49, 95% CI: 0.33–0.72), constipation (RR=0.38, 95% CI: 0.26–0.57), and nausea (RR=0.50, 95% CI: 0.37–0.68). However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.Conclusions: S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.Systematic review registration: Prospero, identifier CRD42024549780.


4 February 2022 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
YXYing Xie
Ying Xie
HLHui Li
Hui Li
LZLinyan Zhou
Linyan Zhou
FTFeng Tian
Feng Tian
To the Editors, Vedolizumab is a gut-selected humanized α4β7 integrin antibody, which reduces intestinal inflammation by inhibiting lymphocyte migration to the gut. Recently, vedolizumab has been increasingly used in the treatment of moderately to severely active ulcerative colitis (UC). Vedolizumab safety assessment showed a high safety profile with low incidence rates of serious infections, malignancy events, and <5% of infusion-related reactions.1 The results from the vedolizumab GEMINI long-term safety (LTS) study have further established its safety.2 Here, we report a case of acute allergic reaction following the fifth infusion of vedolizumab in a patient with refractory UC. A 26-year-old woman with a history of UC for 10 years, who was refractory to corticosteroids, received 4 doses of vedolizumab (300 mg) for 15 weeks. The patient experienced severe abdominal colic, shortness of breath, dizziness, and numbness in the limbs after 5 minutes of intravenous (IV) administration of fifth vedolizumab...

15 February 2022 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
HLHui Li
Hui Li
HSHong Shu
Hong Shu
YXYing Xie
Ying Xie
HZHong Zhang
Hong Zhang
MCMingming Cui
Mingming Cui
FTFeng Tian
Feng Tian
To the Editors: Hypoganglionosis (HG) is a rare condition characterized by a reduced number of ganglion cells within the colonic submucosal (Meissner) and myenteric (Auerbach) plexuses. The most common clinical manifestations are chronic constipation or pseudo-obstruction.1 Definitive diagnosis is only possible by full-thickness biopsy; therefore, the condition is difficult to diagnose preoperatively. Herein, we present a rare case of recurrent intestinal obstruction and intestinal ulcers, which was finally diagnosed as multisegmental HG after 3 operations. A 56-year-old Chinese man was admitted to hospital in September 2018 with symptoms of recurrent bowel obstruction for 1 year. Colonoscopy showed ulcers around the hepatic flexure. Computed tomography enterography showed gross dilation of the ascending and transverse colon ( Figure 1A). Right hemicolectomy was performed, and Crohn’s disease was suspected postoperatively. However, constipation recurred immediately. In February 2019, he visited our hospital with intestinal bleeding. Computed tomography enterography showed obvious dilation of...